RxDoctor Payments Data

Louis Hagler, MD

Family Medicine · Phoenix, AZNPI 1740509181

Payments from drug & device makers

$364in general payments, 2019–2025

Across 11 payments — averaging $33.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$116
  • Endo USA, Inc.$78
  • Medtronic$42
  • Teleflex LLC$42
  • Johnson & Johnson$23
  • Boston Scientific$21
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$24868%
  • Education$11632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk1$116
Endo USA, Inc.3$78
Medtronic1$42
Teleflex LLC1$42
Johnson & Johnson1$23
Boston Scientific1$21
Profound Medical Corp.1$18
Astellas Pharma US Inc1$15
Pfizer1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$364 in reported general payments places this provider in the 55th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$176,587
Medicare patients
660
Services billed
4,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$52,614
JardianceEmpagliflozin33$47,277
EliquisApixaban41$41,982
XareltoRivaroxaban16$22,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$19,610
MounjaroTirzepatide15$14,465
Breo ElliptaFluticasone/Vilanterol17$10,205
Atorvastatin Calcium565$4,588
Rosuvastatin Calcium272$4,204
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,368
Levothyroxine Sodium329$3,267
Novolog FlexpenInsulin Aspart15$2,974
Albuterol Sulfate HfaAlbuterol Sulfate82$2,430
Tamsulosin Hcl137$2,316
SynthroidLevothyroxine Sodium17$2,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$52,61449 claims
PfizerEliquis$11$41,98241 claims
Johnson & JohnsonXarelto$23$22,27916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →